We Offer Worldwide Shipping
Login Wishlist

5,7-Diacetoxy-3,4‘,8-trimethoxyflavone

$1,216

  • Brand : BIOFRON

  • Catalogue Number : BN-O1540

  • Specification : 98%(HPLC)

  • CAS number : 5128-43-8

  • Formula : C22H20O9

  • Molecular Weight : 428.4

  • PUBCHEM ID : 13916287

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BN-O1540

Analysis Method

HPLC,NMR,MS

Specification

98%(HPLC)

Storage

-20℃

Molecular Weight

428.4

Appearance

Yellow powder

Botanical Source

This product is isolated and purified from the herbs of Micromelum sp.

Structure Type

Flavonoids

Category

Standards;Natural Pytochemical;API

SMILES

CC(=O)OC1=CC(=C(C2=C1C(=O)C(=C(O2)C3=CC=C(C=C3)OC)OC)OC)OC(=O)C

Synonyms

4H-1-Benzopyran-4-one, 5,7-bis(acetyloxy)-3,8-dimethoxy-2-(4-methoxyphenyl)-/5,7-dihydroxy-3,4',8-trimethoxyflavone diacetate/5,7-Diacetoxy-3,8,4'-trimethoxy-flavon/5,7-diacetoxy-3-pyridin-3-yl-chromen-2-one/3,8-Dimethoxy-2-(4-methoxyphenyl)-4-oxo-4H-chromene-5,7-diyl diacetate/3-O-Methyl-prudomestin-diacetat

IUPAC Name

[7-acetyloxy-3,8-dimethoxy-2-(4-methoxyphenyl)-4-oxochromen-5-yl] acetate

Density

1.4±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

260.3±30.2 °C

Boiling Point

599.1±50.0 °C at 760 mmHg

Melting Point

InChl

InChl Key

PKVJLPXCFDHGEY-UHFFFAOYSA-N

WGK Germany

RID/ADR

HS Code Reference

2915390000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:5128-43-8) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

7800509

Abstract

The tetrabutylammonium salt of guanosine 5′-monophosphate (5′-GMP) dissolves in DMSO-d6 forming aggregated species which exhibit some properties of reverse micelles. 1H NOESY experiments show that the 5′-GMP adopts the syn conformation about the glycosidic bond. Molecular mechanics calculations reveal a stable structure with this conformation in which the phosphate group and the amino group of the base are in close enough proximity to hydrogen bond. In contrast inosine 5′-monophosphate in DMSO-d6, which has no NH2 group for hydrogen bond stabilization of the syn conformation, is shown by NMR to have the anti structure. Guanosine in DMSO-d6 behaves differently from 5′-GMP. Guanosine adopts the anti conformation and forms a symmetric dimer via hydrogen bonding between the N3 and NH2 of the bases.

Title

Conformation, hydrogen bonding and aggregate formation of guanosine 5'-monophosphate and guanosine in dimethylsulfoxide.

Author

R T West, L A Garza, 2nd, W R Winchester, and J A Walmsley

Publish date

1994 Nov 25;

PMID

13638609

Title

Exercise and Heart Disease*

Author

Kenneth W. Donald

Publish date

1959 Apr 18; 1

PMID

27872259

Abstract

Hallucinations constitute one of the 5 symptom domains of psychotic disorders in DSM-5, suggesting diagnostic significance for that group of disorders. Although specific featural properties of hallucinations (negative voices, talking in the third person, and location in external space) are no longer highlighted in DSM, there is likely a residual assumption that hallucinations in schizophrenia can be identified based on these candidate features. We investigated whether certain featural properties of hallucinations are specifically indicative of schizophrenia by conducting a systematic review of studies showing direct comparisons of the featural and clinical characteristics of (auditory and visual) hallucinations among 2 or more population groups (one of which included schizophrenia). A total of 43 articles were reviewed, which included hallucinations in 4 major groups (nonclinical groups, drug- and alcohol-related conditions, medical and neurological conditions, and psychiatric disorders). The results showed that no single hallucination feature or characteristic uniquely indicated a diagnosis of schizophrenia, with the sole exception of an age of onset in late adolescence. Among the 21 features of hallucinations in schizophrenia considered here, 95% were shared with other psychiatric disorders, 85% with medical/neurological conditions, 66% with drugs and alcohol conditions, and 52% with the nonclinical groups. Additional differences rendered the nonclinical groups somewhat distinctive from clinical disorders. Overall, when considering hallucinations, it is inadvisable to give weight to the presence of any featural properties alone in making a schizophrenia diagnosis. It is more important to focus instead on the co-occurrence of other symptoms and the value of hallucinations as an indicator of vulnerability.

KEYWORDS

schizophrenia, bipolar disorder, psychosis, nonclinical

Title

Hallucinations: A Systematic Review of Points of Similarity and Difference Across Diagnostic Classes

Author

Flavie Waters*,1,2 and Charles Fernyhough3,4

Publish date

2017 Jan;


Description :

Empty ...